Aelis Farma pockets $30M; Alcyone unveils $23M for AAV gene therapies; Progentec and GSK collaborate; Kozin bags $60M
Jun 10, 2021
Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder...
Read More
Biogen’s Alzheimer’s Drug; FDA approval to Novo Nordisk’s Wegovy; Bluebird’s Gene Therapy
Jun 8, 2021
Verdict for Biogen’s Long-Awaited Alzheimer’s Drug Is Finally Here The USFDA finally gave approval to eagerly-anticipated Biogen’s Drug Aducanumab for the...
Read More
Latest Medtech Commercial, Regulatory and Clinical Updates For – Abbott, BD, CooperVision, Procyrion, TricValve, and others
Jun 3, 2021
Abbott receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System for Aortic Stenosis treatment On May 17, 2021, Ab...
Read More
Pieris-Genentech deal; Xilio inks deal with Merck; BMS taps Xencor’s tech; GenSight’s gene therapy reports partial recovery
May 27, 2021
Pieris Pharmaceuticals declares Respiratory and Ophthalmology deal with Genentech Pieris, a clinical-stage biotechnology company, declared that it has entered into a multi-...
Read More
MedTech Industry: Commercial, Regulatory and Clinical Updates
May 20, 2021
HCmed Signs a Global Development Agreement with CSL Behring to develop a combination product On May 04, 2021, HCmed has announced the start of a strategic partnership with ...
Read More
Lilly ink deal with MiNA; Appia Bio aims for CAR-T with $52M raise; Nuvalent raises $135M; Orchard gene therapy benefits kids
May 13, 2021
Lilly, MiNA ink agreement to upregulate proteins using RNA Eli Lilly will utilise the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology plat...
Read More
Pfizer hit by DMD delay & halts BCMA trials; Sarepta’s drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic
May 6, 2021
Pfizer suffers a DMD delay and halts BCMA trials amid safety woes Pfizer has paused after seeing three cases of peripheral neuropathy in an early-stage study, enrollm...
Read More
Arch Oncology scores $105M; Abbott’s new coronary imaging platform; Lilly scraps IL-23 psoriasis program; Biogen offer access to experimental ALS med
Apr 29, 2021
Arch Oncology scores USD 105 Million for anti-CD47 med in solid tumors, multiple myeloma Arch Oncology scored USD 105 million from new and old backers to expand the drug’...
Read More
Vertex leads in CRISPR Therapeutics deal; Update for Phase 2 clinical trial of KVD824; Ovid dumps lead program; Virta Health pulls in $133M
Apr 22, 2021
Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies ...
Read More
Lilly’s Retevmo shows promise; CeQur tanks up on $110M in funding; Repertoire secures $189M; Recursion sets terms for $306M IPO
Apr 15, 2021
Lilly’s RET inhibitor Retevmo exhibits early promise in new cancer types The phase 1/2 LIBRETTO-001 trial enrolled 32 patients with 12 unique RET fusion-positive advanced...
Read More
Taysha Acquires Rare Disease Gene Therapy For $5.5 M; AZ’s Farxiga Fails In COVID-19 Study; Sanofi To Strengthen Its Vaccines Manufacturing Capacities
Apr 13, 2021
Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading pa...
Read More
Artios collaborates with Novartis; Scholar Rock eyes Phase III trial; Novavax starts crossover arms in Covid-19 trials; Volastra nabs $44M
Apr 8, 2021
Artios Pharma announces collaboration with Novartis to tap next-generation DDR cancer therapies Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploitin...
Read More
Amgen to acquire Rodeo for $55M; Novartis expands radioligand portfolio; Organon acquires Alydia for $240M; Forma announces positive FT-4202 dose levels
Apr 1, 2021
Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, ...
Read More
Asher Bio raises $55M; Roche halts Huntington’s phase 3 trial; Novartis’ radioligand hits goal in phase 3; EpimAb raises $120M in Series C
Mar 25, 2021
Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseas...
Read More
GBT strikes a deal with Sanofi; Lilly’s IL-23 inhibitor shows promise; Glooko raises $30M; FDA uplifts hold on Solid’s DMD gene therapy
Mar 18, 2021
Global Blood Therapeutics strikes a deal with Sanofi for sickle cell disease programs As Global Blood Therapeutics works to bring its sickle cell disease drug, Oxbryta, to ...
Read More
